department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Eliquis · pharmadog

pharmadog
drugs
Eliquis

drug

patient view →

apixaban ODT

Marketedupdated 2mo ago

by Bristol-Myers Squibb Co

Approved

annual revenue · 2024–2024peak $13.3B

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 14 investigational indications.

all catalysts(1)

phase 2 completion · 1

News(0)

no news has mentioned this drug yet

brand

Eliquis

generic

apixaban

MOA

Coagulation factor X inhibitor

indication

Venous Thromboembolism

phase

marketed

approved

2012-12-28

phase 2 completion

Medical University of Gdansk — apixaban (Phase II Trial Completion)

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 21, 2026

137 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

May 22, 2041patentUS 11896586*PED
Nov 22, 2040formulationUS 11896586
Aug 24, 2031patentUS 9326945*PED
Aug 24, 2031patentUS 9326945*PED
Aug 24, 2031patentUS 9326945*PED
Feb 24, 2031formulationUS 93269454.6y
Feb 24, 2031formulationUS 93269454.6y
Feb 24, 2031formulationUS 93269454.6y
May 21, 2027patentUS 6967208*PED318d
May 21, 2027patentUS 6967208*PED318d
May 21, 2027patentUS 6967208*PED318d
May 21, 2027patentUS 6967208*PED318d
Nov 21, 2026compositionUS 6967208137d
Nov 21, 2026compositionUS 6967208137d
Nov 21, 2026compositionUS 6967208137d
Nov 21, 2026compositionUS 6967208137d

FDA exclusivities (8)

Oct 17, 2028PEDPediatric (6mo bonus)2.3y
Oct 17, 2028PEDPediatric (6mo bonus)2.3y
Oct 17, 2028PEDPediatric (6mo bonus)2.3y
Oct 17, 2028PEDPediatric (6mo bonus)2.3y
Apr 17, 2028NPPNew Product (3y)1.8y
Apr 17, 2028NPPNew Product (3y)1.8y

Apr 17, 2028

NS

NS

1.8y

Apr 17, 2028NPNP1.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

drugapixaban5 co-mentions · 2 sources
drugapixaban ER5 co-mentions · 2 sources
tagOncology2 co-mentions · 1 sources
tagHematology2 co-mentions · 1 sources
tagAdCom2 co-mentions · 1 sources
tag510(k) Clearance2 co-mentions · 1 sources
tagDiagnostics Company2 co-mentions · 1 sources
companyMedical University of Gdansk1 co-mentions · 1 sources

Trials studying apixaban ODT

phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillationactive not recruitingn=20,284
N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosisrecruitingn=300
phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancersrecruitingn=1,600
phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulationrecruitingn=1,200
phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participantsrecruitingn=186
phase3REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adultsrecruitingn=2,000
—Anticoagulation in Patients With Venous Thromboembolism and Canceractive not recruitingn=1
—High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in Franceactive not recruitingn=1

more trials →